Alpelisib plus fulvestrant for PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer after a CDK4/6 inhibitor
Prof. Hope Rugo
Cohort A of the multinational phase 2 study BYLieve evaluated the combination of alpelisib and fulvestrant for PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer following progression on or after previous therapy including a CDK4/6 inhibitor plus an aromatase inhibitor. At 6 months 61 of 121 patients (50.4%; 95% CI 41.2-59.6) were alive without progression. The toxicity was manageable.
